RCS - Avacta Group PLC - Investor Webinar

AvactaAnnouncement

28/03/2024 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240328:nRSb7860Ia&default-theme=true

RNS Number : 7860I  Avacta Group PLC  28 March 2024

 

 

 

March 28 2024

 

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

 

Investor Webinar

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted oncology drugs and powerful diagnostics, is pleased to announce that
Chief Executive Officer Dr. Alastair Smith will be hosting a webinar on
Wednesday, 10 April 2024 at 5:30pm (BST).

 

The webinar will cover the Company's updated clinical data from the
first-in-human Phase 1 trial of AVA6000, the first of the Company's
pre|CISION™ peptide drug conjugates that targets chemotherapy to the tumor,
which are to be presented at the 2024 American Association for Cancer Research
Annual Meeting, taking place in San Diego, California from 5-10 April 2024.
The updated clinical data will be presented in the Phase 1 Clinical Trials 2
Poster Session on 9 April 2024.

 

There will be a Q&A session for investors after the presentation and
questions can be submitted pre-event as part of the registration process.

 

You can register for the event by using the following link:

https://www.turnerpope.com/register/
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.turnerpope.com%2Fregister%2F&data=05%7C02%7CAndy.Thacker%40TurnerPope.com%7C8296e62546d8483c282208dc4f330598%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638472331397061435%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=i335GQQaZEauqaF00Tbs6%2F1a9qu7mfSDE%2Fk8r0D8tFc%3D&reserved=0)

 

We are delighted to announce that the webinar will be chaired by news and
corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by
Turner Pope Investments.

 

 

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                           Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                    www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

                                                                            Tel: +44 (0) 207 710 7600

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                    www.stifel.com (http://www.stifel.com/)

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good

 Peel Hunt (Joint Broker)                                                   Tel: +44 (0) 207 418 8900

 James Steel / Chris Golden / Patrick Birkholm                              www.peelhunt.com (http://www.peelhunt.com)

 ICR Consilium (Media and IR)                                               avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 Webinar enquiries                                                          +44 (0) 20 3657 0050

 Turner Pope Investments (TPI) Limited                                      www.turnerpope.com

 James Pope / Andrew Thacker

 

 

 

 

About Avacta Group plc - https://www.avacta.com (https://www.avacta.com/)

 

Avacta Group is a UK-based company focused on improving healthcare outcomes
through targeted cancer treatments and diagnostics.

 

Avacta has two divisions: an oncology biotech division harnessing proprietary
therapeutic platforms to develop novel, highly targeted cancer drugs, and a
diagnostics division, focused on supporting healthcare professionals and
broadening access to testing. Avacta's two proprietary platforms, Affimer®
and pre|CISION™ underpin its cancer therapeutics whilst the diagnostics
division leverages the Affimer® platform to drive competitive advantage in
its markets.

 

The pre|CISION™ platform modifies chemotherapy to be activated only in the
tumor tissue, reducing systemic exposure and toxicity. This is achieved by
harnessing an enzyme called FAP which is highly upregulated in most solid
tumors compared with healthy tissues, turning chemotherapy into a "precision
medicine". The lead pre|CISION™ programme, AVA6000 a tumour activated form
of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in
safety compared with standard doxorubicin, and early signs of clinical
activity.

 

 

To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKFBPPBKDCNB